Palvella Therapeutics (PVLA) Stock: Buy, Sell, or Hold?
PVLA - Palvella Therapeutics, Inc. Common Stock
$126.39
-0.19 (-0.15%)
▼
5d:
-0.75%
30d:
-15.49%
90d:
-8.42%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 10, 2026
17d
Get Alerted When PVLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PVLA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: PVLA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: PVLA is currently trading at $126.39, which is considered slightly low relative to its 30-day fair value range of $126.19 to $148.31.
Technical Outlook: Technically, PVLA is in a uptrend. Immediate support is located at $118.22, while resistance sits at $139.86.
Market Sentiment: PVLA scores 90/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $231.25 (+83.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PVLA is in a uptrend. Immediate support is located at $118.22, while resistance sits at $139.86.
Market Sentiment: PVLA scores 90/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $231.25 (+83.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$126.19 -
$148.31
Company Quality Score
68/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
95.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (90/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 83.0% below Wall St target ($231.25)
- BULLISH: Bottoming setup score 90/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$126.19 -
$148.31
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$9.20
(7.3%)
Support & Resistance Levels
Support Level
$118.23
Resistance Level
$139.86
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.84
Wall Street Target
$231.25
(+83.0%)
Share & Embed Analysis
Last updated: October 22, 2026 8:32 PM ET
Data refreshes hourly during market hours. Next update: 9:32 PM
Data refreshes hourly during market hours. Next update: 9:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PVLA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 68 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 71 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 60 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$153 | 68 BUY |
|
PTGX
Protagonist Therapeutics… |
STRONG BUY
14 analysts |
$178 | 64 BUY |
